IL29

(redirected from Il-29)

IL29

A gene on chromosome 19q13.13 that encodes interleukin-29, an immunomodulatory cytokine which upregulates MHC class-I antigen expression. It has potent antiviral activity and has antitumour activity. IL29 is a ligand for the heterodimeric class-II cytokine receptor composed of IL10RB and IL28RA, which is thought to act via the JAK-STAT pathway.
References in periodicals archive ?
Kotenko is being honored for his seminal co-discovery and cloning of the type III interferons (IFN lambda1, 2, and 3 or IL-29, IL-28A and B) and their receptors; this work was published in Nature Immunology.
The company completed start-up of its pilot-scale protein manufacturing facility and began GMP manufacturing of IL-29 to supply clinical trials planned for 2006.
Advancement of both TACI-Ig and IL-21 into Phase 2 studies, and the start of IL-29 clinical testing, will make 2006 a very important year for the company's long-term success.
IL-29 is being manufactured in ZymoGenetics' pilot scale manufacturing facility in Seattle, Washington.
IL-29 is generated in response to viral infection and preclinical data has shown anti-viral activity comparable to that of alpha-interferon.
PEG-Interferon lambda is a member of the Type III lambda interferon family, which includes IL-28A, IL-28B and IL-29 (also known as interferon lambda 2, 3, and 1, respectively).
IL-29 is a member of the type 3 Interferon family, which includes IL-28A and IL-28B, and signals through the same receptor as IL-28A and IL-28B.
SEATTLE -- Pipeline expands to include IL-29, potential treatment for Hepatitis C, as fourth product candidate; Important clinical milestones also reported
These included a milestone payment from Novo Nordisk related to the start of IL-21 clinical trials outside North America; fees earned from Novo Nordisk related to the license of IL-28, IL-29 and IL-31 outside North America; and continued recognition of IL-20 license fee revenue received from Novo Nordisk earlier this year.
future genomics-derived protein development candidates such as IL-29 and
IL-28A and IL-29 show potential in providing immunity to viral infection, and Interleukin 31 (IL-31) is believed to play a role in stimulating cellular infiltration and inflammation.